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Summary
Objective: Osteoarthritis (OA) is one of the most common diseases among the elderly. The main characteristic is the progressive destruction
of articular cartilage. We lack quantitative and sensitive biomarkers for OA to detect changes in the joints in an early stage of the disease. In
this study, we investigated whether a urinary metabolite proﬁle could be found that could serve as a diagnostic biomarker for OA in humans.
We also compared the proﬁle we obtained previously in the guinea pig spontaneous OA model.
Methods: Urine samples of 92 participants (47 non-OA controls and 45 individuals with radiographic OA of the knees or hips) were selected
from the Johnston County Osteoarthritis Project (North Carolina, USA). Participants ranged in age from 60 to 84 years. Samples were
measured by 1H nuclear magnetic resonance spectroscopy (NMR) with subsequent principal component discriminant analysis and partial
least squares regression analysis.
Results: Differences were observed between urine NMR spectra of OA cases and controls (P! 0.001 for both male and female subjects). A
metabolite proﬁle could be determined which was strongly associated with OA. This proﬁle largely resembled the proﬁle previously identiﬁed
for guinea pigs with OA (w40 out of thew125 signals of the human proﬁle were present in the guinea pig proﬁle as well). A correlation was
found between the metabolite proﬁle and radiographic OA severity (R2Z 0.82 (male); R2Z 0.93 (female)).
Conclusion: This study showed that a urine metabolite proﬁle may serve as a novel discriminating biomarker of OA.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA), or cartilage degeneration, is the most
common form of arthritis1. An important feature of the
disease is the progressive destruction of articular tissues,
resulting in impaired movement, pain and ultimately
disability. A variety of systemic and local risk factors have
been identiﬁed that predispose to the development of OA,
including age, gender, bone density, obesity, joint injury and
nutritional factors2. Despite the growing knowledge on the
pathogenesis of OA, its etiology is still not clear and
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Received 15 February 2005; revision accepted 14 April 2005.7effective disease-modifying treatment is lacking. Diagnosis
of OA is currently based on clinical symptoms3e5 in
combination with radiology. Radiological evaluation of joints
mainly images bone and is relatively insensitive: a follow-up
period of 2 years is often needed to assess disease
progression6. Magnetic Resonance Imaging has the ability
to simultaneously visualize all joint tissues. The technique is
currently being optimized but has not yet reached its full
potential.
Alternative methods are therefore needed in order to
detect osteoarthritic changes in the joints in an early stage
of the disease in a quantitative, reliable, and sensitive
manner. Biomarkers that monitor molecular events taking
place during disease are well suited for this purpose. A good
biomarker is disease-speciﬁc, reﬂects actual disease pro-
gression, is sensitive to changes due to therapeutic
intervention and can predict disease outcome. Currently,
no single biomarker exists that meets these requirements6.
Combining several biomarkers has been shown to improve
the discriminatory capability considerably7. Recent develop-
ments in the ﬁeld of metabolomics now provide the tools to
go one step further: identify proﬁles of metabolites that62
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urine and blood, contain a large number of metabolites that
may provide valuable information on the metabolism of an
organism, and thus about its health status. Metabolic
proﬁling, also referred to as metabolomics, metabonomics8,
or related terms, is deﬁned as the quantitative and
qualitative analysis of the whole complement of small
molecules in a sample (cell, tissue, body ﬂuids, etc.). The
technology has emerged from approaches to the proﬁling of
body ﬂuid that were developed many decades ago for the
study of inborn errors of metabolism and the effects of
nutrition. Our previous research has shown that such a
metabolomics approach is also feasible for identifying
a biomarker proﬁle for OA. We discovered differences
between urine samples of 10- and 12-month-old Hartley
guinea pigs that spontaneously develop OA using nuclear
magnetic resonance spectroscopy (NMR) and multivariate
data analysis (MVDA). A metabolite proﬁle was detected
which was strongly associated with OA10. For initial
metabolic proﬁling it was essential to use samples from
a well-deﬁned animal study, rather than using human
material, since differences in OA severity, medication, diet
and habits create additional variability that would greatly
hinder the identiﬁcation of an OA-speciﬁc urinary metabolic
proﬁle in humans. However, once identiﬁed amidst the
numerous other metabolites, the urinary metabolic proﬁle
for OA in the guinea pig model may also be quantiﬁed in
humans. The present study was initiated from this assumptionand designed to identify a biomarker proﬁle that could
distinguish unaffected from OA affected individuals.
Subjects, materials and methods
STUDY POPULATION AND SAMPLE SELECTION
Urine samples of 92 subjects were obtained from
participants in the ongoing Johnston County Osteoarthritis
Project (North Carolina, USA), that is described in detail
elsewhere11. Participants were selected who were not using
any medicine for joint complaints (NSAIDs (non-steroidal
anti-inﬂammatory drug) and COX-2 (cyclooxygenase)
inhibitors), varied in age between 60 and 84 years, and
had a body mass index (BMI) between 21 and 34. Radio-
graphic knee OA was deﬁned from weight bearing bilateral
anteroposterior radiographs of the knee, according to the
KellgreneLawrence (KeL) grading scheme12. An OA case
was deﬁned as KeL grade R 2 of at least two joints out of
the four joints considered (knees and hips); controls were
deﬁned as KeL grade 0 in both knees and 0 or 1 in both hips.
The selected group of participants consisted of 47 controls
(20 males and 27 females) and 45 patients with radiographic
knee and/or hip OA (21 males and 24 females). Bone
mineral density measurements (hip and spine) were
performed with a Lunar DPXIQ dual-energy X-ray absorpti-
ometry machine. Unpaired t test (SPSS 11.5) was used to
compare controls and cases for adequate matching (Table I).Table I
The characteristics of the OA and control participants
Control P value Case
Mean (sd) Range Mean (sd) Range
Female
Number 27 24
Age [years] 69.5 (6.0) [60e84] 0.253 67.7 (4.8) [61e77]
Height [inches] 63.2 (2.0) [57.5e66.5] 0.183 62.4 (2.3) [58.3e65.5]
Weight [lbs] 161 (26) [109e198] 0.411 156 (25) [106e204]
BMI 28.4 (4.3) [20.9e34.0] 0.715 28.0 (3.5) [21.9e33.9]
BMD left hip 0.86 (0.1) [0.55e1.16] 0.049 0.93 (0.1) [0.65e1.18]
BMD spine 1.00 (0.2) [0.49e1.31] 0.112 1.08 (0.2) [0.73e1.46]
Affected joint [#] 0.0 (0.0) [0e0] !0.001 2.4 (0.7) [2e4]
KeL grade right knee 0.0 (0.0) [0e0] !0.001 1.3 (1.1) [0e3]
KeL grade left knee 0.0 (0.0) [0e0] !0.001 1.5 (1.2) [0e4]
KeL grade right hip 0.9 (0.3) [0e1] !0.001 1.8 (0.7) [0e3]
KeL grade left hip 1.0 (0.2) [0e1] !0.001 1.7 (0.7) [0e3]
Summed KeL grade 1.9 (0.5) [0e2] !0.001 6.2 (1.6) [4e9]
Current NSAID use none none
Current COX-2 inhibitor use none none
Male
Number 20 21
Age [years] 66.9 (4.0) [61e75] 0.512 67.8 (4.8) [61e76]
Height [inches] 68.4 (3.0) [61.0e73.5] 0.774 68.1 (2.9) [63.3e73.5]
Weight [lbs] 177 (17) [144e212] 0.090 188 (23) [139e237]
BMI 26.6 (2.2) [24.0e31.4] 0.032 28.4 (3.0) [23.6e34.0]
BMD left hip 0.98 (0.1) [0.74e1.31] 0.453 1.01 (0.2) [0.76e1.52]
BMD spine 1.18 (0.2) [0.89e1.59] 0.566 1.21 (0.1) [0.96e1.54]
Affected joint [#] 0.0 (0.0) [0e0] !0.001 2.2 (0.6) [2e4]
KeL grade right knee 0.0 (0.0) [0e0] !0.001 1.5 (1.0) [0e3]
KeL grade left knee 0.0 (0.0) [0e0] !0.001 1.3 (1.0) [0e3]
KeL grade right hip 0.8 (0.4) [0e1] !0.001 1.7 (0.7) [0e3]
KeL grade left hip 0.9 (0.3) [0e1] !0.001 1.6 (0.5) [1e2]
Summed KeL grade 1.7 (0.6) [0e2] !0.001 6.1 (1.4) [4e10]
Current NSAID use none none
Current COX-2 inhibitor use none none
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centrifuged at 3000 rpm for 10 min to remove debris, and
stored at 80(C until analyses. The study was approved by
the Institutional Review Board of the University of North
Carolina School of Medicine and the Centers for Disease
Control and Prevention. Written informed consent was
obtained from all participants.
NMR ANALYSIS OF URINE SAMPLES
Prior to NMR spectroscopic analysis, 1 mL urine samples
were lyophilized and reconstituted in 1 mL sodium phos-
phate buffer (0.1 mmol/L, pH 6.0, made up with D2O), to
minimize spectral variance arising from differences in
urinary pH. Sodium trimethylsilyl-[2,2,3,3,-2H4]-1-propionate
(TMSP; 0.025 mmol/L) was added as an internal standard.
NMR measurements were carried out in random order and
in triplicate in a fully automated manner on a 600 MHz
spectrometer (Avance, Bruker BioSpin GmbH, Rheinstetten,
Germany), using a proton NMR set-up operating at a temper-
ature of 300 K. For each sample, 256 free induction decays
(FID) were collected. Each FID was induced using a 45(
pulse, an acquisition time of 4.10 s and a relaxation delay of
2 s. The FIDs were collected as 64 K data points with
a spectral width of 12,000 Hz. The spectra were processed
using the standard Bruker software. An exponential window
function with a line broadening of 0.5 Hz and a manual
baseline correction were applied to all spectra. After
referring to the internal NMR reference (TMSP dZ 0.0),
line listings were prepared with the standard Bruker NMR
software. To obtain these listings all lines in the spectra
above a threshold corresponding to about three times the
signal-to-noise ratio were collected and converted to a data
ﬁle suitable for MVDA applications. The NMR data ﬁle was
imported into Winlin (V2.1, TNO, The Netherlands). Minor
variations from comparable signals in different NMR spectra
were adjusted and lines were ﬁtted without loss of
resolution, after which MVDA was carried out.
MULTIVARIATE DATA ANALYSIS
To correct for urinary dilution NMR data were centered
and scaled to unit variance so that small and large peaks
contributed similarly to the ﬁnal study result. Subsequently,
Winlin was used to perform principal component discrimi-
nant analysis (PCDA) on the data. PCDA is a powerful tool
to identify and maximize differences between pre-deﬁned
groups in data sets with a large number of variables13. In
this study, health status (controls vs OA cases) was used as
a priori knowledge for PCDA discrimination. For PCDA
analysis, the respective data set was randomly divided into
a training data set and a test data set. PCDA models were
built upon the training data set. Next, the test data set was
used to test the accuracy of the PCDA model by passing it
through this model to obtain the model’s prediction of
classiﬁcation of the test data into the clusters from the
PCDA training model. Predictions were within the 95%
conﬁdence interval.
The resulting discriminants were quantiﬁed for each of the
urinary NMR spectra. In a two-category discriminant ap-
proach, all variance (100%) is explained by the ﬁrst
discriminant. To visualize the differences between NMR
spectra of controls and OA cases, the scores of the ﬁrst
discriminant were plotted and the unpaired t test was
performed to evaluate the statistical signiﬁcance of the
difference between the PCDA scores of the two groups [Excel
Ofﬁce 2003, Microsoft Corporation, USA; Fig. 1(A and C)].Subsequently, the original NMR spectra were used to
calculate which metabolites contributed to the PCDA scores
that distinguished controls from OA cases (for male and
female cases separately). The combination of these
metabolites (visualized via the position in ppm within the
NMR spectrum) formed (gender-speciﬁc) metabolic proﬁles
for OA. These metabolic proﬁles provided insight into the
type of metabolites responsible for the difference in PCDA
scores of the two groups.
Partial least square (PLS) regression analysis was
carried out in Matlab (Version 6.5, The MathWorks Inc.,
Natick, MA, USA) using the PLS toolbox (Version 3.0,
Eigenvector Research Inc., Manson, WA, USA) to correlate
urine NMR spectra with the sum of knee and hip KeL
grades, a measure for OA status. Leave-one-out was used
as a method for cross-validation to obtain a goodness of ﬁt
(R2) for the PLS model in its prediction of KeL grades from
the urine NMR spectra. The PLS regression vectors,
showing NMR signals that were correlated to the KeL
grade, were plotted using Excel.
Results
DESCRIPTION OF SAMPLE
The characteristics of the OA and control participants are
given in Table I. To minimize variation in urinary metabolites
(and thus increase the chance of ﬁnding an OA-speciﬁc
metabolic ﬁngerprint) male and female subjects were
analyzed separately and for both genders, cases and
controls were matched for age, height and weight. Unpaired
t test was used to compare controls and cases for adequate
matching (Table I). No consistent statistically signiﬁcant
differences were observed except for the presence of OA.
The OA patients had a summed KeL grade (knee and hips)
ranging from 4 to 10 while the control subjects had
a summed KeL grade ranging from 0 to 2.
HUMAN URINARY METABOLITE PROFILE
The underlying hypothesis of the present study is that OA
leads to, or is accompanied by, metabolic disturbances that
are reﬂected in an aberrant urinary metabolite composition.
NMR with subsequent MVDA revealed such OA-related
alterations in the urinary metabolite composition, resulting in
a metabolic biomarker ﬁngerprint that distinguished healthy
individuals without OA from individuals with OA.
When applying PCDA on the male and female NMR data
sets, clear differences for both genders were observed
between the NMR spectra of OA cases and controls
(P! 0.001 for both male and female subjects). Plots of the
PCDA scores clearly showed this [Fig. 1(A and C)]. Thus,
PCDA resulted in a distinct separation (minimal overlap)
between groups based on the metabolite composition and
metabolite concentration of urine which is characteristic for
each group. In other words, a speciﬁc combination of meta-
bolites can almost fully distinguish OA cases from controls.
The proﬁles of these metabolites for male and female
subjects are shown in Fig. 1(B and D). In these ‘ﬁngerprints’,
NMR signals of urinary metabolites were depicted according
to their relative abundance in OA vs non-OA subjects. NMR
signals of the metabolic proﬁle that displayed an association
withOA for bothmales aswell as females and that showed up
in the same direction were d 1.18, 2.02, 2.22, 2.38, 2.58, 2.74,
3.02, 3.14, 3.18, 3.22, 3.26, 3.70, 3.74, 3.78, 3.94 ppm in the
positive direction and d 1.38, 3.58, 3.98, 7.02, 7.06, 7.10,
7.54, 7.58, 7.62, 7.66, 7.78, 7.82 and 7.86 ppm in the
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Fig. 1. Plot of the scores of urinary NMR spectra of male (A) and female (C) participants without OA vs participants with OA (the points
represent the complete urinary NMR spectra of the subjects). The prevalence of OA is reﬂected by the urinary composition, as there is a clear
difference between the scores of the two groups (P! 0.001 for both male and female subjects). In addition, metabolite proﬁles of male (B) or
female (D) participants without OA vs participants with OA. Peaks (representing NMR signals, expressed in ppm) in the positive direction
indicate metabolites that are more abundant in urine of participants with OA than in urine of participants without OA. Consequently,
metabolites that are less abundant in urine of OA subjects as compared to the controls are presented as peaks in the negative direction.
Signals that were also found in the guinea pig OA study are indicated. Please note that some signals are present in the metabolite proﬁles of
male subject but not in female subjects and vice versa. These are therefore not representing OA-speciﬁc metabolites, rather they reﬂect the
gender difference.negative direction. Signals at d 3.06 ppm in a positive
direction and d 2.14, 2.18, 3.30, 3.62, 7.14, 7.38 ppm in the
negative direction varied strongly between males and
females.
METABOLITE PROFILE IN RELATION TO SUMMED K–L GRADE
PLS regression was performed to correlate urine NMR
spectra with the summed knee and hip KeL grades of
subjects. A model was obtained that could predict the KeL
grade from the urine NMR spectra for male participants
(R2Z 0.82) and female participants (R2Z 0.93) (Fig. 2, left
and right panel, respectively), thus showing the sensitivity of
the metabolite proﬁle for OA. The NMR patterns (thus
metabolite proﬁles) that were shown by PLS regression to
be correlated to the KeL grade, were largely similar to the
metabolite proﬁles obtained by PCDA on controls vs OA
cases, respectively (Fig. 3). NMR signals that correlated toOA and that showed similar patterns in men and women
were d 1.18, 2.38, 2.58, 2.74, 3.10, 3.14, 3.18, 3.70, 3.74,
3.78, 3.94 ppm in a positive direction and d 1.38, 3.58, 3.98,
7.02, 7.10, 7.54, 7.58, 7.62, 7.66, 7.82 and 7.86 ppm in
a negative direction.
IDENTITIES OF NMR SIGNALS
Although the NMR signals that make up the ﬁngerprints
are not yet characterized (which would require extensive
mass spectroscopy), rough identiﬁcation of the metabolites
can be done based on the comparison of their NMR pattern
with databases containing NMR signatures of known
molecules. According to these databases, the NMR signals
at d 1.18, 2.38, 2.58, 2.74, 3.10, 3.14, 3.18, 3.70, 3.74, 3.78,
3.94 ppm in the positive direction (levels increased with OA)
represent, among others, metabolites like hydroxybutyrate,
pyruvate, creatine/creatinine and glycerol. Signals at d 1.38,
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Fig. 2. Plot of measured summed KeL grades vs predicted summed KeL grades from urine NMR proﬁles for male (A) and female (B)
participants, obtained with a PLS model. The goodness of ﬁt (R2) of the model is 0.93 and 0.82 for male and female subjects, respectively,
showing that the correlation between KeL grades and the urine metabolite proﬁle is high.3.58, 3.98, 7.02, 7.06, 7.10, 7.54, 7.58, 7.62, 7.66, 7.78,
7.82 and 7.86 ppm in a negative direction (levels decreased
with OA) represent, among others, compounds like histidine
and methylhistidine.
Discussion
A biomarker for OA that is useful for early disease
detection, that reﬂects the course of joint destruction, and
that predicts long-term outcome is currently lacking14.
Such a biomarker could be used to assess disease
progression and the effects of therapy and thereby serve
as an outcome measure in clinical trials. Ultimately, an
ideal OA biomarker would potentially facilitate the de-
velopment of effective individualized treatment plans and
approaches.Classical biomarker development, based on the detection
of known tissue synthesis and resorption markers, has thus
far not yielded biomarkers sufﬁciently speciﬁc and/or
sensitive enough for the above mentioned applications6.
The progress in the ﬁeld of metabolomics and in particular
NMR with subsequent MVDA has heralded the advent of
a new approach to OA biomarker development. From the
overall mixture of metabolites in a biological ﬂuid like urine,
a combination of molecules can be identiﬁed that together
best reﬂect a disease process8.
In the present study, we were able to discriminate
between subjects who did not have OA and subjects with
radiological OA, based on small differences in urinary
metabolite composition and metabolite levels as detected
by NMR and subsequent MVDA. We identiﬁed a urine
metabolite proﬁle that was strongly associated with OA and-0.25
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Fig. 3. Plot showing the NMR signals that correlate to the KeL grades according to PLS for both male and female participants. Peaks
(representing NMR signals) in the positive direction indicate metabolites that are more abundant in urine of patients with OA than in urine of
participants without OA. Consequently, metabolites that are less abundant in urine of participants with OA are presented as peaks in the
negative direction. There is a large similarity with the metabolite proﬁles obtained with PCDA.
767Osteoarthritis and Cartilage Vol. 13, No. 9which appeared in male as well as in female subjects. A
regression model showed that this metabolite proﬁle
correlated with the summed KeL scale of radiological OA,
for male as well as female subjects. Hence, from the
metabolite proﬁle it was possible to discriminate between
OA cases and controls and, moreover, to predict the OA
state and severity in a sensitive manner. The metabolite
proﬁle that we identiﬁed in human samples strongly
resembled the one we identiﬁed previously in samples from
the guinea pig model for OA10. This further supports the
supposition that the metabolite proﬁle could serve as
a biomarker for OA.
In addition to its use as a biomarker for OA, the OA-
speciﬁc metabolic ﬁngerprint also provides information on
the cellular processes that occur during the disease and as
such, the metabolic proﬁle contributes to our understanding
of the pathophysiology of the disease. The presence of
hydroxybutyrate, pyruvate, creatine/creatinine and glycerol
in the metabolite proﬁle could point to an enhanced use of
fat, and hence an altered energy utilization. Since the
present study was conducted in urine, which reﬂects
changes in all body tissues, the current data cannot
distinguish between general changes in the body metabo-
lism vs local changes in the joint tissues. However, the
current data are consistent with studies described in the
literature in which the involvement of altered energy
metabolism in OA has been proposed based on measure-
ments in normal and osteoarthritic canine synovial ﬂuid15. It
is possible that some of the metabolites associated with OA
are intermediaries in these metabolic pathways.
The metabolite proﬁle for human OA also indicated an
alteration in histidine metabolism. Our results demonstrated
lower levels of histidine and methylhistidine in association
with OA. Again, based on our urinary data, no distinction
can be made between a local change in the joint or
systemically altered histidine metabolism. However, this
ﬁnding is consistent with the hypothesis that histidine is
metabolised into histamine, itself responsible for stimulating
the proliferation of articular chondrocytes into clusters,
a characteristic of OA cartilage16,17. The synthesis of
histamine from histidine is catalyzed by histidine decarbox-
ylase18,19 and both histamine and histidine decarboxylase
have been demonstrated in chondrocytes of OA carti-
lage16,17. These results would suggest that lowered levels
of histidine may be caused by over-expression of histidine
decarboxylase. However, more studies are needed to
conﬁrm this hypothesis.
In conclusion, our study provides evidence of a diagnostic
metabolite proﬁle associated with OA that correlates with
KeL grades. Our ﬁndings are consistent with other studies
reporting effects on altered energy and histidine metabolism
in association with OA. The metabolite proﬁle may provide
a sensitive outcome measurement tool that can be used to
evaluate the effects of nutrients and drugs on the incidence
and progression of the disease. Results are promising but
further research will be necessary to validate this hypoth-
esis. Moreover, this metabolite proﬁle may provide a tool to
allow physicians to better quantify the extent of disease.
Mass spectroscopy-based identiﬁcation of the unknown
metabolites will be an important next step in promoting an
understanding of the disease
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